BRAF and glioblastoma: However, while some signals of efficacy were observed in subgroups such as BRAF-mutant GBM [128], which is rare in adult GBM, the overall clinical benefit for unselected patients has been limited, with outcomes largely comparable to standard therapy alone [122,123,124,128,129].